← Back to Search

Dance Therapy for Neuropathy in Breast Cancer Survivors

N/A

Recruiting

Led By Lise Worthen-Chaudhari, PhD, MFA

Research Sponsored by Ohio State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Breast cancer survivor stage I-III

Symptomatic for neuropathy

Must not have

Use of cytotoxic or immunotherapy during study (endocrine therapy allowed)

Non-ambulatory or lower extremity amputation (assistive devices allowed)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months post-intervention

Awards & highlights

No Placebo-Only Group

Summary

This trial will study the effect of group dance classes on quality of life and physical health for cancer survivors.

Who is the study for?

This trial is for breast cancer survivors who have finished taxane-based chemotherapy at least 3 months ago, are experiencing neuropathy symptoms, and have balance issues. They must be able to follow study instructions. It's not for those with severe diabetes, vestibular deficits, lower limb amputations, or those in physical therapy.

What is being tested?

The study tests the effects of group dance classes using Tango and rhythmic auditory stimulation on quality of life and physical health among breast cancer survivors suffering from neuropathy.

What are the potential side effects?

While specific side effects aren't listed for dancing or rhythmic auditory stimulation, participants may experience fatigue or discomfort related to exercise. The social nature of tango could also affect emotional well-being positively or negatively.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a breast cancer survivor of stage I, II, or III.

Select...

I experience symptoms of nerve damage.

Select...

My balance is poor and I'm middle-aged without a brain injury.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not using any cancer-killing drugs or immunotherapy during the study, but hormone therapy is okay.

Select...

I use assistive devices due to not being able to walk or having a leg amputation.

Select...

My diabetes is not well-controlled (A1C > 8).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months post-intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months post-intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post-intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Brief Pain Inventory Short Form

Cancer-Related Fatigue

Clinical measure of balance function

+6 more

Other study objectives

Quantified Clinical Measure of Balance Function

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: TangoExperimental Treatment1 Intervention

The intervention will consist of 16 Argentine Tango (Tango) sessions, adapted for neurorehabilitation per Hackney and Earhart (2010). Delivered over 8 weeks at a frequency of 2x per week and duration of 1 hour per session, this program teaches the basics steps of partnered Tango dance.

Group II: Home Exercise (HEX)Active Control1 Intervention

The control group will consist of an evidence-based, structured home exercise program (HEX) based on the 8 week intervention described by Zimmer et al (2018) and recommended by physical therapists specializing in BC within our organization. This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Rhythmic Auditory Stimulation

2018

N/A

~10

0 / 6Eligibility criteria met